Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer

Clinical Breast Cancer

Volumn 14, Issue 1, 2014, Pages 13-19

  Schwartzberg, Lee S ^a   Wang, Grace ^b   Somer, Bradley G ^a   Blakely, L Johnetta ^c   Wheeler, Benton M ^a   Walker, Mark S ^d   Stepanski, Edward J ^d   Houts, Arthur C ^d  

^a WEST CLINIC   (United States)

^b Advanced Medical Specialties   (United States)

^c Tennessee Oncology   (United States)

^d ACORN Research LLC   (United States)

Author keywords

Chemoendocrine; ER PR positive; Faslodex; Low dose chemotherapy; Progression free survival; Xeloda

Indexed keywords

AROMATASE INHIBITOR; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BODY WEIGHT; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; DYSPNEA; EVENING DOSAGE; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERPIGMENTATION; HYPOKALEMIA; LABORATORY TEST; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EMBOLISM; METRONOMIC DRUG ADMINISTRATION; MIDDLE AGED; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERY ELDERLY; VOMITING;

CHEMOENDOCRINE; ER-/PR-POSITIVE; FASLODEX; LOW DOSE CHEMOTHERAPY; PROGRESSION-FREE SURVIVAL; XELODA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; ESTRADIOL; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; POSTMENOPAUSE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84892811705     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.09.003     Document Type: Article

References (33)

1. A. Howell Pure oestrogen antagonists for the treatment of advanced breast cancer Endocr Relat Cancer 13 2006 689 706
2. A. Howell, J.F. Robertson, and J. Quaresma Albano et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 2002 3396 3403
3. C.K. Osborne, J. Pippen, and S.E. Jones et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 2002 3386 3395
4. S. Chia, W. Gradishar, and L. Mauriac et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT J Clin Oncol 26 2008 1664 1670
5. J.F. Robertson, B. Erikstein, and K.C. Osborne et al. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer Clin Pharmacokinet 43 2004 529 538
6. A. Di Leo, G. Jerusalem, and L. Petruzelka et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer J Clin Oncol 28 2010 4594 4600
7. A.D. Seidman, J. O'Shaughnessy, and J.L. Misset Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 7 suppl 6 2002 20 28
8. C.M. Walko, and C. Lindley Capecitabine: a review Clin Ther 27 2005 23 44
9. B.T. Hennessy, A.M. Gauthier, and L.B. Michaud et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in the literature Ann Oncol 16 2005 1289 1296
10. R. Leonard, B.T. Hennessy, and J.L. Blum et al. Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer Clin Breast Cancer 11 2011 349 356
11. T. Taguchi, T. Nakayama, and N. Masuda et al. Study of low-dose capecitabine monotherapy for metastatic breast cancer Chemotherapy 56 2010 166 170
12. K.I. Pritchard Combining endocrine agents with chemotherapy: which patients and what sequence? Cancer 112 2008 718 722
13. J. Baselga, M. Campone, and M. Piccart et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529
14. S.R. Johnston, L.S. Kilburn, and P. Ellis et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial Lancet Oncol 14 2013 989 998
15. J. Bergh, P.E. Jonsson, and E.K. Lidbrink et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer J Clin Oncol 30 2012 1919 1925
16. R.S. Mehta, W.E. Barlow, and K.S. Albain et al. Combination anastrozole and fulvestrant in metastatic breast cancer N Engl J Med 367 2012 435 444
17. M.M. Oken, R.H. Creech, and D.C. Tormey et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
18. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
19. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 2003 National Cancer Institute Washington, DC
20. A.P. Abernethy, J.E. Herndon 2nd, and J.L. Wheeler et al. Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/tablet data-collection system in academic oncology J Pain Symptom Manage 37 2009 1027 1038
21. A.P. Abernethy, S.Y. Zafar, and H. Uronis et al. Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients J Pain Symptom Manage 40 2010 545 558
22. B. Fortner, S. Baldwin, and L. Schwartzberg et al. Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation J Pain Symptom Manage 31 2006 207 214
23. A.C. Houts, D. Lipinski, and J.P. Olsen et al. Use of the patient care monitor to screen for depression in adult cancer patients interviewed with the structured clinical interview for DSM-IV Psychooncology 19 2010 339 407
24. E.J. Stepanski, M.S. Walker, and L.S. Schwartzberg et al. The relation of trouble sleeping, depressed mood, pain and fatigue in patients with cancer J Clin Sleep Med 5 2009 132 136
25. M.S. Walker, L.S. Schwartzberg, and E.J. Stepanski et al. A retrospective study of quality of life in a community sample of patients with early stage breast cancer Breast Cancer Res Treat 115 2009 415 422
26. M. Yoshimoto, S. Takao, and M. Hirata et al. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer Cancer Chemother Pharmacol 70 2012 331 338
27. S.D. Young, R.M. Lafrenie, and M.J. Clemons Phase II trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer Curr Oncol 19 2012 e75 e83
28. Z. Wang, J. Lu, and S. Leaw et al. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study Cancer Chemother Pharmacol 69 2012 515 522
29. P. Fedele, A. Marino, and L. Orlando et al. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer Eur J Cancer 48 2012 24 29
30. S. Dellapasqua, F. Bertolini, and V. Bagnardi et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer J Clin Oncol 26 2008 4899 4905
31. E. Bajetta, G. Procopio, and L. Celio et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women J Clin Oncol 23 2005 2155 2161
32. L.S. Lindstrom, E. Karlsson, and U.M. Wilking et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression J Clin Oncol 30 2012 2601 2608
33. J.F. Robertson, A. Llombart-Cussac, and J. Rolski et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study J Clin Oncol 27 2009 4530 4535